Linrodostat
Based on 7 publication(s) in Google Scholar
Linrodostat (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 value of 1.1 nM in IDO1-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 1923833-60-6
- Formula: C24H24ClFN2O
- Molecular Weight:410.91
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Linrodostat
More- Immunity. 2021 Oct 12;54(10):2354-2371.e8. [Abstract]
- Cell Death Differ. 2021 Feb;28(2):715-729. [Abstract]
- MedComm (2020). 2026 Mar 30;7(4):e70709. [Abstract]
- J Neuroinflammation. 2024 Nov 28;21(1):307. [Abstract]
- Cell Rep. 2024 Sep 13;43(9):114741. [Abstract]
- Heidelberg University. 2025.
- SSRN. 2023 Dec 1.
Biological Activity
|
IDO1 1.1 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
1.1 μM
Compound: 63; BMS-986205
|
Inhibition of IDO1 in HEK293 cells
Inhibition of IDO1 in HEK293 cells
|
[PMID: 32055299] |
| HeLa | IC50 |
2.8 nM
Compound: BMS-986205
|
Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells using L-tryptophan as substrate incubated for 48 hrs by fluorescence assay
Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells using L-tryptophan as substrate incubated for 48 hrs by fluorescence assay
|
[PMID: 32832022] |
Linrodostat (0.01-100 μM; 72 hours; SKOV-3 and Jurkat clone E6-1 cells) treatment reduces the number of viable cells compared with the non-treated control. Linrodostat also induces cell death at much lower concentrations and its IC50 is 6.3 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SKOV-3 and Jurkat clone E6-1 cells
-
Concentration:0.01-100 μM
-
Incubation Time:72 hours
-
Result:Reduced the number of viable cells compared with the non-treated control and induced cell death at much lower concentrations.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1923833-60-6
-
Appearance Solid
-
Molecular Weight 410.91
-
Formula C24H24ClFN2O
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(Cl)C=C1)[C@H](C)[C@@](CC2)([H])CC[C@H]2C3=CC=NC4=C3C=C(F)C=C4
-
Synonyms
BMS-986205; ONO-7701
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. [Abstract]2021 Oct 12;54(10):2354-2371.e8. PMID: 34614413 -
Cell Death Differ
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. [Abstract]2021 Feb;28(2):715-729. PMID: 32929219 -
MedComm (2020)
Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression. [Abstract]2026 Mar 30;7(4):e70709. PMID: 41930352 -
J Neuroinflammation
Taprenepag restores maternal-fetal interface homeostasis for the treatment of neurodevelopmental disorders. [Abstract]2024 Nov 28;21(1):307. PMID: 39609821 -
Cell Rep
Integrated metabolic-transcriptomic network identifies immunometabolic modulations in human macrophages. [Abstract]2024 Sep 13;43(9):114741. PMID: 39276347 -
-
Solvent & Solubility
DMSO : 50 mg/mL (121.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.06 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4336 mL | 12.1681 mL | 24.3362 mL | 60.8406 mL |
| 5 mM | 0.4867 mL | 2.4336 mL | 4.8672 mL | 12.1681 mL | |
| 10 mM | 0.2434 mL | 1.2168 mL | 2.4336 mL | 6.0841 mL | |
| 15 mM | 0.1622 mL | 0.8112 mL | 1.6224 mL | 4.0560 mL | |
| 20 mM | 0.1217 mL | 0.6084 mL | 1.2168 mL | 3.0420 mL | |
| 25 mM | 0.0973 mL | 0.4867 mL | 0.9734 mL | 2.4336 mL | |
| 30 mM | 0.0811 mL | 0.4056 mL | 0.8112 mL | 2.0280 mL | |
| 40 mM | 0.0608 mL | 0.3042 mL | 0.6084 mL | 1.5210 mL | |
| 50 mM | 0.0487 mL | 0.2434 mL | 0.4867 mL | 1.2168 mL | |
| 60 mM | 0.0406 mL | 0.2028 mL | 0.4056 mL | 1.0140 mL | |
| 80 mM | 0.0304 mL | 0.1521 mL | 0.3042 mL | 0.7605 mL | |
| 100 mM | 0.0243 mL | 0.1217 mL | 0.2434 mL | 0.6084 mL |
Linrodostat Related Classifications
HY-101560 Related Classifications
Powered by Bioz